TransCure bioServices SAS is accredited by the french Ministère de l’Enseignement Supérieur et de la Recherche MESR and the Haut Conseil des Biotechnologies to perform in vivo pharmacology studies for worldwide international customers.
As a preferred CRO for our customer’s in vivo pharmacology studies, our team members emphasize competence, transparency, and enthusiasm. We are pro-active and SOP driven to deliver the highest quality results our clients demand.
Regarding animal welfare, we apply the strictest regulation in compliance with the national laws of France, are AAALAC certified, and adhere to our own rigorous standards:
We are committed to the 3Rs: Replacement, Reduction, and Refinement, to sound science, and to the responsible use of animals, which are treated with the highest standards of care and ethics. We only work with highly qualified staff, who are trained regularly in order to ensure the best treatment of research animals.
In addition to the inspections by government authorities, we have a formal program of regular peer reviews of our internal animal and laboratory research facilities, conducted by the biopark’s ethical committee and an independent veterinarian.
“And I would like to sincerely thanks TransCure for working so diligently with us through these issues with really great transparency.”
Adaptable and professional
“Thank you so much for the final report. Yes, we made it indeed! The report looks great. Thank you so much for being adaptable, professional, and accommodating to us throughout this process. This was an important study for us and it’s truly been a pleasure to work with you. I have also really appreciated how accessible you made yourself. I felt like I could get in touch with you whenever! I look forward to more collaborations in the future.”
Wonderful to work with!
“We are very satisfied with the level of professionalism, care, and rigor with which you conducted the project. We look forward to continued collaboration in the future. Our dedicated Project Leader was great at communicating with us and was wonderful to work with.”
Our team is composed of highly experienced scientists. We look forward to working with you!
Patrick Nef, Phd, Co-Founder and Chief Executive Officer (CEO) and acting CBO (Chief Business Officer). Patrick Nef holds a PhD from the University of Geneva (Switzerland) and has over 30 years of experience in R&D and early drug development in academia, biotechnology industry, small and large pharmaceuticals and non-for-profit public-private partnership foundation. He co-founded TransCure bioServices SAS in 2012 to develop human immune system mouse models for immuno-oncology, infectious and inflammation diseases. Previously he served as Chief Business Officer at Medicines for Malaria Venture from 2008 to 2011 to assist their efforts to reduce the burden of malaria in endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. He was Chief Scientific Officer at Synosia Therapeutics Inc. from 2006 to 2008 to develop drugs for neuro-degenerative and psychiatric disorders, Chief Executive Officer at Faust Pharmaceutical SA in 2005 to develop CNS drugs and as Global Business Director, Vice-President & Disease Area Head for CNS at F. Hoffmann-La Roche Ltd. from 1996-2005. Before that he was Assistant Professor in the Biochemistry Department at the University of Geneva, Switzerland from 1992 and has published more than 46 peer-reviewed articles/reviews/patents.
Sebastien Tabruyn, PhD, General Manager and Chief Scientific Officer (CSO). Sebastien Tabruyn holds a PhD in Molecular Biology from the University of Liege (Belgium). After 15 years of experience as Project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 as Head of Molecular Biology and Oncology. Sebastien Tabruyn published 35 peer-reviewed publications in the field of Oncology, Angiogenesis, Inflammation and Immunity.
Kiave-Yune Ho Wang Yin, PhD, Director of Innovation and Business Development. Kiave Ho Wang Yin holds a PhD in Immunology/Oncology from the Paris 7 University (France). She worked for 5 years in the Center of Cardiovascular Research (Paris) as scientist in the field of inflammation and angiogenesis. She has published more than 10 papers in peer-reviewed international journals in oncology and inflammation. She is a highly experienced scientist in R&D research and in vivo pharmacology preclinical mouse models and joined the company in 2016.
Catherine Verhaeghe, PhD, Director of Operations. Catherine Verhaeghe holds a PhD in Molecular Biology from the University of Liege (Belgium). She joined David Erle Lab at UCSF (USA) where she identified new molecules involved in goblet cell hyperplasia in lung and intestinal diseases. She has expertise in Project/Team Management, In vivo mouse models, Inflammation, Signalling Pathway and Oncology. She published more than 10 papers in peer-reviewed international journals in the field of Cystic fibrosis, airway and intestinal inflammation, oncology.
Antoine Poskin, DVM, PhD, Veterinary Chief Officer. Antoine started his career as a veterinarian, then worked as scientific researcher for Iprabio (Mons, Belgium), the Blood Brain Barrier Laboratory (LBHE, Lens, France) and Sciensano (formerly Veterinary and Agrochemical Research Centre, Brussels, Belgium). Antoine published 11 peer-reviewed articles and obtained a PhD in Veterinary Science from the University of Liege (Belgium). After his PhD, he first joined the respiratory franchise of Novartis as Medical Sciences Liaison, then moved to TransCure bioServices as Veterinary Chief Officer and Animal Facility Manager.
He makes sure that corporate policy meets the highest quality and ethical standards for our clients. Dr. Poskin was instrumental in TransCure bioService’s AAALAC accreditation.
Hendrick Claeys, Global Sales Director, is in charge of implementing and supporting our sales activities by identifying new market opportunities and defining the actions required to bring a new dynamic to our business development. His vision and experience within the life-science field helps to position TransCure bioServices as the leader in preclinical humanized mice services.
Oriane Ferrera, Business Development Manager, holds a master’s degree in Sciences of Marketing from the Dublin business school with a specialization in Public Relations and Events. Dedicated to our customers, she is the main point of contact to assist you in the elaboration of your preclinical studies at TransCure.
Ornella Filizzola, Business Development Assistant, holds a master’s degree in Biomedical Sciences, Medical from Amsterdam. She was a research Assitant in Venezuela at the Institute of Advanced Studies and Product Specialist at Biochrom CorpBiochrom Corp. At Transcure bioservices, she is responsible for assisting clients with all administrative matters and preparing proposals.